Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
Industry, Sector and Symbol
Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:TR
CUSIPN/A
Phone+1-416-5950627
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-259.65%
Return on Assets-55.25%
Miscellaneous
EmployeesN/A
Outstanding Shares64,470,000
Market CapC$136.73
Trillium Therapeutics (TSE:TR) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TR."
How were Trillium Therapeutics' earnings last quarter?
Trillium Therapeutics Inc (TSE:TR) announced its quarterly earnings data on Friday, May, 11th. The company reported ($0.65) EPS for the quarter, topping the Zacks' consensus estimate of ($0.80) by $0.15. View Trillium Therapeutics' Earnings History.
When is Trillium Therapeutics' next earnings date?
What is the consensus analysts' recommendation for Trillium Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Calvin R. Stiller M.D., Independent Chairman of the Board
- Niclas Stiernholm, President, Chief Executive Officer, Director
- James T. Parsons, Chief Financial Officer
- Malik Slassi, Senior Vice President - Discovery Research
- Robert Uger, Chief Scientific Officer
- Scott Duncan, Director of Intellectual Property
- Penka Petrova, Chief Development Officer
- Eric L Sievers, Chief Medical Officer
- Luke M. Beshar CPA, Independent Director (Age 59)
- Henry Friesen M.D., Independent Director (Age 79)
Has Trillium Therapeutics been receiving favorable news coverage?
News headlines about TR stock have trended somewhat positive recently, according to Accern. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Trillium Therapeutics earned a media sentiment score of 0.03 on Accern's scale. They also gave news articles about the company an impact score of 46.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Trillium Therapeutics?
Shares of TR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trillium Therapeutics' stock price today?
One share of TR stock can currently be purchased for approximately C$30.20.
How big of a company is Trillium Therapeutics?
Trillium Therapeutics has a market capitalization of C$136.73 million.
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TSE TR)
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TR will underperform the S&P 500 over the long term. You may vote once every thirty days.
